BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33055588)

  • 21. Survival risk prediction model for patients with pT
    Qi Z; Hu Y; Qiu R; Li J; Li Y; He M; Wang Y
    J Cardiothorac Surg; 2021 May; 16(1):121. PubMed ID: 33933129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological parameters predicting recurrence of pT1N0 esophageal squamous cell carcinoma.
    Xue LY; Qin XM; Liu Y; Liang J; Lin H; Xue XM; Zou SM; Zhang MY; Zhang BH; Hui ZG; Zhao ZT; Ren LQ; Zhang YM; Liu XY; Yuan YL; Ying JM; Gao SG; Song YM; Wang GQ; Dawsey SM; Lu N
    World J Gastroenterol; 2018 Dec; 24(45):5154-5166. PubMed ID: 30568392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Lymphatic metastasis intensity of and lymphadenectomy for thoracic esophageal squamous cell carcinoma].
    Lu ZM; Zhang H; Wang MH; Cui DH; Yang YQ; Huang HZ
    Ai Zheng; 2006 May; 25(5):604-8. PubMed ID: 16687083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ypN0 in Patients With Definitive cN-positive Status After Preoperative Treatment Is a Prognostic Factor in Esophageal Cancer.
    Yoshida T; Nishino T; Goto M; Inoue S; Fujiwara S; Takizawa H; Tangoku A; Uehara H; Bando Y
    Anticancer Res; 2022 Jan; 42(1):195-203. PubMed ID: 34969725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis.
    Akita H; Doki Y; Yano M; Miyata H; Miyashiro I; Ohigashi H; Ishikawa O; Nishiyama A; Imaoka S
    Dis Esophagus; 2009; 22(4):291-7. PubMed ID: 19021686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
    Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung.
    Suntharalingam M; Paulus R; Edelman MJ; Krasna M; Burrows W; Gore E; Wilson LD; Choy H
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):456-63. PubMed ID: 22543206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of the survival in patients after surgical resection of thoracic esophageal cancer].
    Zhang HL; Liu RL; Shi YT; Wang ZC; Wang BH; Li YJ; Zhou LY; Ping YM
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):541-5. PubMed ID: 19950705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
    Lee J; Lee KE; Im YH; Kang WK; Park K; Kim K; Shim YM
    Ann Thorac Surg; 2005 Oct; 80(4):1170-5. PubMed ID: 16181835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
    Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
    Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
    Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
    BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant Therapy for Node-Positive Esophageal Cancer After Induction and Surgery: A Multisite Study.
    Semenkovich TR; Subramanian M; Yan Y; Hofstetter WL; Correa AM; Cassivi SD; Inra ML; Stiles BM; Altorki NK; Chang AC; Brescia AA; Darling GE; Allison F; Broderick SR; Etchill EW; Fernandez FG; Chihara RK; Litle VR; Muñoz-Largacha JA; Kozower BD; Puri V; Meyers BF
    Ann Thorac Surg; 2019 Sep; 108(3):828-836. PubMed ID: 31229485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma.
    Tsuchikawa T; Miyamoto M; Yamamura Y; Shichinohe T; Hirano S; Kondo S
    Ann Surg Oncol; 2012 May; 19(5):1713-9. PubMed ID: 21822560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
    Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H
    Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Associated factors of postoperative relapse and metastasis in pT1bN0M0-pT4aN0M0 thoracic esophageal squamous cell carcinoma].
    Pan W; Xiang Y; Gu Z; Ji C; Mao T; Fang W
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1045-1049. PubMed ID: 28900998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients.
    Kadota T; Hatogai K; Yano T; Fujita T; Kojima T; Daiko H; Fujii S
    Cancer Sci; 2018 Jun; 109(6):2046-2055. PubMed ID: 29601131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
    Miyazawa M; Katsuda M; Maguchi H; Katanuma A; Ishii H; Ozaka M; Yamao K; Imaoka H; Kawai M; Hirono S; Okada KI; Yamaue H
    Int J Cancer; 2017 Feb; 140(4):973-982. PubMed ID: 27861852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
    Brown TA; Mittendorf EA; Hale DF; Myers JW; Peace KM; Jackson DO; Greene JM; Vreeland TJ; Clifton GT; Ardavanis A; Litton JK; Shumway NM; Symanowski J; Murray JL; Ponniah S; Anastasopoulou EA; Pistamaltzian NF; Baxevanis CN; Perez SA; Papamichail M; Peoples GE
    Breast Cancer Res Treat; 2020 Jun; 181(2):391-401. PubMed ID: 32323103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma.
    Wang J; Wu N; Zheng QF; Yan S; Lv C; Li SL; Yang Y
    World J Gastroenterol; 2014 Dec; 20(48):18397-403. PubMed ID: 25561808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.